HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041.
Related Questions
How will the USPTO patent allowance for cadisegliatin affect VTVT's valuation and market perception?
What is the expected timeline for cadisegliatin's clinical trial progression and potential FDA approval?
How does the patent term through 2041 impact the long‑term revenue potential and competitive moat for VTVT?
What are the potential market size and revenue forecasts for an oral adjunctive therapy to insulin in type 1 diabetes?
How might this patent news influence VTVT's partnership or licensing opportunities with larger pharmaceutical companies?
What are the risks of patent challenges or prior‑art disputes that could affect the enforceability of the cadisegliatin patents?
How does cadisegliatin’s mechanism of action compare to existing T1D treatments and other pipeline candidates from competitors?
Will the patent allowance trigger any milestone payments or trigger clauses in existing collaborations or financing agreements?
How might the market react to the sentiment score of 70 and the overall positive tone of the release?
What is the potential impact on VTVT’s stock volatility and trading volume in the short term following the announcement?